CPRIT suspends first cycle of awards for FY21

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cancer Prevention and Research Institute of Texas has suspended its first cycle of grant applications for fiscal year 2021 for Academic Research, Product Development Research and Prevention Program awards.

CPRIT is taking this action in response to the unexpected impact to the budget from the COVID-19 pandemic and a projected decrease in oil and gas revenues. CPRIT continues to evaluate releasing Requests for Applications for fiscal year 2021 and is committed to doing so if circumstances support it.

CPRIT has closed the FY 21.1 Academic Research Program RFAs listed below (originally due June 3). CPRIT will not accept applications responding to these RFAs and will withdraw any FY 21.1 applications already submitted.

Applications for the second cycle of fiscal year 2020 (FY 20.2) are undergoing peer review. CPRIT is not withdrawing the FY 20.2 applications and expects to announce awards in August or early fall.

  • RFA R-21.1 – RTA Research Training Awards

  • RFA R-21.1 – IIRA Individual Investigator Research Awards

  • RFA R-21.1 – IIRACCA Individual Investigator Research Awards for Cancer in Children and Adolescents

  • RFA R-21.1 – IIRACT Individual Investigator Research Awards for Clinical Translation

  • RFA R-21.1 – IIRACSBC Individual Investigator Research Awards for Computational Systems Biology of Cancer

  • RFA R-21.1 – IIRAP Individual Investigator Research Awards for Prevention and Early Detection

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login